1. Home
  2. RLI vs ROIV Comparison

RLI vs ROIV Comparison

Compare RLI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RLI Corp. (DE)

RLI

RLI Corp. (DE)

HOLD

Current Price

$65.26

Market Cap

5.9B

Sector

Finance

ML Signal

HOLD

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$21.67

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLI
ROIV
Founded
1965
2014
Country
United States
United Kingdom
Employees
1147
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
14.1B
IPO Year
1985
N/A

Fundamental Metrics

Financial Performance
Metric
RLI
ROIV
Price
$65.26
$21.67
Analyst Decision
Hold
Strong Buy
Analyst Count
6
8
Target Price
$72.80
$21.94
AVG Volume (30 Days)
727.4K
6.7M
Earning Date
01-21-2026
11-10-2025
Dividend Yield
4.10%
N/A
EPS Growth
N/A
N/A
EPS
3.82
N/A
Revenue
$1,855,871,000.00
$20,329,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.83
$376.94
P/E Ratio
$16.84
N/A
Revenue Growth
5.16
N/A
52 Week Low
$57.75
$8.73
52 Week High
$86.05
$22.45

Technical Indicators

Market Signals
Indicator
RLI
ROIV
Relative Strength Index (RSI) 62.42 62.44
Support Level $60.91 $20.14
Resistance Level $63.35 $21.48
Average True Range (ATR) 1.09 0.71
MACD 0.19 0.00
Stochastic Oscillator 97.12 65.96

Price Performance

Historical Comparison
RLI
ROIV

About RLI RLI Corp. (DE)

RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: